Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telbivudine antiviral therapy after liver resection for HBV-related hepatocellular carcinoma
ChiCTR-OCH-13004570Phase 4Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of telbivudine in hepatocellular carcinoma (HCC) and hepatitis B (HBV) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: long-term survival rate and recurrence rate. Started Dec 2013; status: completed.
02
Drugs
telbivudine
03
Conditions
hepatocellular carcinoma (HCC)hepatitis B (HBV)
Beyond the preview
Go deeper on ChiCTR-OCH-13004570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OCH-13004570.